Claros | $30,000,000 | (Mar 20, 2026)
Avtal | $24,000,000 | (Mar 20, 2026) Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
PADO AI | $6,000,000 | (Mar 20, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)